Abstract

A trimodal, precision-timed release tablet that delivers a trimodal release profile is provided. The tablet includes at least three immediate release components of buspirone where the release times are controlled by an erosion barrier layer.

IPC Classes  ?

• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

A single dosage form that delivers a tripulse (i.e., three pulses) release profile is provided. The dosage form includes at least three dosage units inside the final dosage form. By providing a single dosage form with multiple dosage units, the dosing frequency is decreased since precise blood levels of the active over a prolonged time period are controlled and achieved.

IPC Classes  ?

• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate

Abstract

A trimodal, precision-timed pulsatile release tablet that delivers a trimodal (i.e., three pulses) release profile is provided. The tablet includes at least three stimulant layers. By providing a single tablet with multiple stimulant layers, the dosing frequency is decreased, and compliance is expected to increase since precise blood levels of the active pharmaceutical ingredient over a prolonged time period are controlled and achieved.

IPC Classes  ?

• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate

Goods & Services

Pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder (ADHD)

Abstract

A trimodal, precision-timed release tablet that delivers a trimodal release profile is provided. The tablet includes at least three immediate release components of buspirone where the release times are controlled by an erosion barrier layer.

IPC Classes  ?

• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 25/22 - Anxiolytics

Abstract

A trimodal, precision-timed release tablet that delivers a trimodal release profile is provided. The tablet includes at least three immediate release components of buspirone where the release times are controlled by an erosion barrier layer.

IPC Classes  ?

• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 25/22 - Anxiolytics
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

A trimodal, precision-timed pulsatile release tablet that delivers a trimodal (i.e., three pulses) release profile is provided. The tablet includes at least three stimulant layers. By providing a single tablet with multiple stimulant layers, the dosing frequency is decreased, and compliance is expected to increase since precise blood levels of the active pharmaceutical ingredient over a prolonged time period are controlled and achieved.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

A trimodal, precision-timed pulsatile release tablet that delivers a trimodal (i.e., three pulses) release profile is provided. The tablet includes at least three stimulant layers. By providing a single tablet with multiple stimulant layers, the dosing frequency is decreased, and compliance is expected to increase since precise blood levels of the active pharmaceutical ingredient over a prolonged time period are controlled and achieved.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Goods & Services

conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention deficit hyperactivity disorder (ADHD)

Goods & Services

Research and development services in the field of pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals

Goods & Services

Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)

Goods & Services

Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)

Goods & Services

Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)

Abstract

A single dosage form that delivers a tripulse (i.e., three pulses) release profile is provided. The dosage form includes at least three dosage units inside the final dosage form. By providing a single dosage form with multiple dosage units, the dosing frequency is decreased since precise blood levels of the active over a prolonged time period are controlled and achieved.

IPC Classes  ?

• A61K 9/22 - Sustained or differential release type

Abstract

A single dosage form that delivers a tripulse (i.e., three pulses) release profile is provided. The dosage form includes at least three dosage units inside the final dosage form. By providing a single dosage form with multiple dosage units, the dosing frequency is decreased since precise blood levels of the active over a prolonged time period are controlled and achieved.

IPC Classes  ?

• A61K 9/22 - Sustained or differential release type
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
• A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine